PF-06412562

DRUG6 trials

Sponsors

Pfizer, University of Zurich, Milton S. Hershey Medical Center, Invicro

Conditions

Decision MakingHealthyHealthy Male VolunteersParkinson DiseaseParkinson's Disease

Early Phase 1

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

CompletedNCT03686501

InvicroHealthy Male Volunteers

Start: 2018-09-10End: 2019-03-28Updated: 2019-04-22

Phase 1

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

CompletedNCT01914796

Start: 2013-08-31End: 2013-12-31Updated: 2014-05-23

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

CompletedNCT02006290

PfizerParkinson's Disease

Start: 2014-03-31End: 2014-08-31Updated: 2015-10-02

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

CompletedNCT02124213

Start: 2014-09-30End: 2014-10-31Updated: 2014-12-17

Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals

CompletedNCT03181841

University of ZurichDecision Making

Start: 2017-05-08End: 2017-12-20Updated: 2020-11-05

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

CompletedNCT03665454

Milton S. Hershey Medical CenterParkinson Disease

Start: 2018-09-24End: 2019-04-21Updated: 2019-07-31